Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762128 | 0.90 | ESR1 (0.33) | DHFRSIGMAR1 | |
| SCHEMBL761406 | 0.90 | ESR1 (0.34) | DHFRCYP1A1CYP1B1SIGMAR1ALDH1A1 | |
| SCHEMBL762131 | 0.89 | IKBKB (0.36) | CYP1A1CYP1B1IKBKBALDH1A1CYP1A2 | |
| SCHEMBL14424428 | 0.89 | SIGMAR1 (0.34) | DHFRCYP1A1CYP1B1SIGMAR1CYP1A2 | |
| SCHEMBL762134 | 0.88 | SIGMAR1 (0.35) | DHFRCYP1A1CYP1B1SIGMAR1 | |
| SCHEMBL760880 | 0.88 | IKBKB (0.35) | CYP1A1CYP1B1IKBKBALDH1A1CYP1A2 | |
| SCHEMBL14099642 | 0.88 | CYP1A1 (0.35) | DHFRCYP1A1CYP1B1IKBKBSIGMAR1 | |
| SCHEMBL761299 | 0.88 | ENPP1 (0.38) | DHFRALDH1A1CYP1A2CYP2C9HSD17B10 | |
| SCHEMBL761290 | 0.87 | IKBKB (0.35) | CYP1A1CYP1B1IKBKBALDH1A1CYP1A2 | |
| SCHEMBL13333637 | 0.87 | SIGMAR1 (0.35) | DHFRCYP1A1CYP1B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902013-B1 | NOVEL ANTHRACENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND ORGANIC ELECTRONIC LIGHT EMITTING DEVICE USING THE SAME | LG CHEMICAL LTD (KR) | 2016-06-01 | — | — | EP | disclosed |
| US-8137823-B2 | Anthracene derivatives, process for preparation thereof, and organic electronic light emitting device using the same | LG CHEM, LTD. (KR) | 2012-03-20 | — | — | US | disclosed |
| US-20090079334-A1 | Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same | LG CHEM, LTD. (KR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090079334-A1 | Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same | XPOT, ALAD, APRT | DHFR 3494/4885CYP1A1 46/4885CYP1B1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.